Sign in Subscribe

Alex Chompff

KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients

Skip to content The CRC Digest KRAS Mutation Sites Associated with Clinical Characteristics in 550 Patients A retrospective study investigated the distribution of specific KRAS mutation sites and their associations with clinicopathological parameters and survival outcomes. (Zhong Nan Da Xue Xue Bao Yi Xue Ban) This content is informational only

Dementia Linked to Lower Surgery Rates and Survival in Stage I-III Colorectal Cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Dementia Linked to Lower Surgery Rates and Survival in Stage I-III Colorectal Cancer Analysis of the Indiana Cancer Registry found that patients with dementia and stage I-III colorectal cancer have increased mortality and receive less invasive evaluations and surgery, with surgery

Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery

Skip to content The CRC Digest ▸ TREATMENT Natural Orifice Specimen Extraction Shows Promise for Rectal Cancer Surgery A multicenter study of 3,385 rectal cancer patients aimed to compare short-term recovery, 6-month functional outcomes, and long-term survival among natural orifice specimen extraction surgery, laparoscopic surgery, and open surgery. (Diseases of

ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH ALK Fusions Identified as Rare but Targetable Drivers in Colorectal Cancer Comprehensive genomic profiling of 56,206 advanced colorectal tumors characterized the prevalence and therapeutic implications of ALK fusions, which are established targets in lung cancer but rare in CRC. (The Oncologist) This

COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT Trial Evaluates Chemoimmunotherapy in dMMR Metastatic Colorectal Cancer A new analysis examines what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer. (Journal of Clinical Oncology)

CRC Research Update — August 07, 2026

Today's colorectal cancer research highlights

Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease

Skip to content The CRC Digest Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant

Direct visualization system aids stent placement in 39-year-old with malignant obstruction

Skip to content The CRC Digest Direct visualization system aids stent placement in 39-year-old with malignant obstruction A case report describes successful use of a direct visualization device to guide enteral stent placement across a stenotic sigmoid colon tumor in a 39-year-old woman with intestinal obstruction. (Frontiers in Medicine) This

Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders

Skip to content The CRC Digest ◇ RESEARCH Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders In 20 patients with MSI-H advanced colorectal cancer receiving immunotherapy, metagenomic sequencing and metabolomics revealed distinct gut microbiota and metabolite patterns associated with clinical benefit versus non-benefit, suggesting the microbiome may influence

Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase II trial tests UGT1A1 genotype-guided high-dose irinotecan rechallenge in refractory metastatic CRC This single-arm phase II study investigated whether patients with refractory metastatic colorectal cancer who previously responded to irinotecan could benefit from high-dose irinotecan rechallenge, with dosing adjusted based on